Labcorp (NYSE: LH) to outline strategy and outlook at Sept. 10 investor day
Rhea-AI Filing Summary
Labcorp Holdings Inc. (NYSE: LH) reported that it will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET. Chairman and CEO Adam Schechter, CFO Julia Wang and other executives plan to present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session. A live webcast and subsequent replay with supporting materials will be available via the company’s investor relations website.
Labcorp describes itself as a global leader in laboratory services with nearly 71,000 employees serving clients in approximately 100 countries. It supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients worldwide.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Investor Day date: September 10, 2026
Employees: 71,000
Countries served: approximately 100 countries
+3 more
6 metrics
Investor Day date
September 10, 2026
Scheduled Investor Day event from 9 a.m. to noon ET
Employees
71,000
Nearly 71,000 employees serving clients globally
Countries served
approximately 100 countries
Geographic footprint of Labcorp’s operations
FDA approvals supported
more than 85%
Share of new drugs and therapeutic products approved by the FDA in 2025 that Labcorp supported
Tests performed
more than 750 million
Annual tests performed for patients around the world
Event time
9 a.m. to noon ET
Duration of the September 10, 2026 Investor Day
Key Terms
Investor Day, capital deployment priorities, long-term financial outlook, webcast, +1 more
5 terms
Investor Day financial
"will host an Investor Day on Thursday, September 10, 2026"
A scheduled event where a company presents its business plan, financial outlook, and strategic priorities directly to investors and analysts; think of it as a detailed road‑map meeting where management explains how they plan to grow and make money. Investors pay attention because the presentations reveal management’s targets, assumptions and risks—new details that can change expectations about future profits and therefore the stock’s value, much like seeing a pilot’s flight plan helps predict where the plane is headed.
capital deployment priorities financial
"discuss the company's go-forward strategy, capital deployment priorities"
long-term financial outlook financial
"capital deployment priorities and long-term financial outlook"
webcast financial
"A live webcast of the event will be available"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
therapeutic products medical
"new drugs and therapeutic products approved by the FDA in 2025"
FAQ
What is Labcorp (LH) announcing in this 8-K filing?
Labcorp is announcing it will host an Investor Day on September 10, 2026, from 9 a.m. to noon ET. Executives will present the company’s go-forward strategy, capital deployment priorities and long-term financial outlook, followed by a Q&A session and webcast replay.
When is Labcorp’s (LH) Investor Day and how can investors attend?
Labcorp’s Investor Day is on September 10, 2026, from 9 a.m. to noon ET. A live webcast will be available on Labcorp’s investor relations website, with a replay and supporting materials accessible after the event concludes.
What topics will be covered at Labcorp’s (LH) Investor Day 2026?
Management will discuss Labcorp’s go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations by senior executives, including the CEO and CFO, will be followed by a question-and-answer session for investors and analysts.
How large is Labcorp’s (LH) global operation according to this disclosure?
Labcorp reports having nearly 71,000 employees serving clients in approximately 100 countries. The company provides diagnostic and drug development services worldwide, highlighting its broad operational scale and global customer reach across healthcare and biopharmaceutical markets.
What role did Labcorp (LH) play in FDA drug approvals in 2025?
Labcorp states it provided support for more than 85% of new drugs and therapeutic products approved by the FDA in 2025. This reflects its extensive involvement in drug development laboratory services for pharmaceutical companies and researchers across multiple therapeutic areas.
How many tests does Labcorp (LH) perform annually as described here?
Labcorp reports performing more than 750 million tests for patients around the world. This volume underscores the scale of its diagnostics operations and its role in helping doctors and hospitals make clinical decisions using laboratory-based insights.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| , | ||||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(Registrant’s telephone number including area code) 336 -229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01. | Regulation FD Disclosure. | ||||
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on August 17, 2026, that it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.
Chairman and Chief Executive Officer Adam Schechter, Executive Vice President and Chief Financial Officer Julia Wang and other members of the executive leadership team will discuss the company's go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations will be followed by a question-and-answer session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 9 a.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. | |||||||
| Exhibit | Exhibit Name | |||||||
| Exhibit 99.1 | Press release dated August 17, 2026 issued by Labcorp Holdings Inc. | |||||||
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
| Date: August 17, 2026 | By: | /s/ KATHRYN W. KYLE | ||||||
| Kathryn W. Kyle | ||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||||
FOR IMMEDIATE RELEASE
| Media | Investors | |||||||
| Racquel White | Dewey Steadman | |||||||
| Media@Labcorp.com | Investor@Labcorp.com | |||||||
Labcorp to Host Investor Day on September 10, 2026
BURLINGTON, N.C., Aug. 17, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 10, 2026, from 9 a.m. to noon ET.
Chairman and CEO Adam Schechter, Executive Vice President and CFO Julia Wang and other members of the executive leadership team will discuss the company's go-forward strategy, capital deployment priorities and long-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 9 a.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.